Technology
Our Approach
We focus on endogenous neuroprotection solutions, leveraging academic research to develop new therapeutic interventions. Our pioneering work on HAEE represents a significant leap forward in enhancing neuronal stability and overall brain health.
We are actively seeking strategic collaborations and scientific partnerships to accelerate HAEE’s clinical translation — including formulation research, biomarker validation, and neuroprotective program alignment with industry and academic partners.
Our Vision
Proteonix is advancing, HAEE, a first-in-class endogenous peptide platform emerging from translational research in neurodegenerative diseases and psychiatry.
Recent analytical studies confirmed HAEE as a natural plasma component with measurable deficiency in cognitive disorders, suggesting a novel pathway for restoring neuronal equilibrium in response to stress.
Latest Preprint
Our Research
Our latest preprint introduces HAEE, an endogenous plasma peptide identified through analytical studies exploring neuroprotective pathways.
The research outlines HAEE’s potential role as a measurable biochemical indicator of adaptive balance in the brain, representing a step toward evidence-based peptide innovation.